Skip to main content
Resources › Psychotropics A-Z › Rivastigmine | Exelon | Exelon
Cholinesterase Inhibitor

Rivastigmine | Exelon

Clinical Overview

Rivastigmine is a cholinesterase inhibitor indicated for mild to moderate dementia of Alzheimer’s disease and Parkinson’s disease dementia. It is available in both oral and transdermal patch formulations, with the patch potentially offering better tolerability and compliance. It inhibits both acetylcholinesterase and butyrylcholinesterase, providing broader cholinergic enhancement.

Primary Clinical Applications

Rivastigmine is indicated for mild to moderate dementia associated with Alzheimer’s disease and Parkinson’s disease. It is the only cholinesterase inhibitor specifically approved for Parkinson’s disease dementia. The transdermal patch may be preferred for patients with swallowing difficulties or GI intolerance to oral formulations.

Mechanism and Clinical Benefits

Rivastigmine reversibly inhibits both acetylcholinesterase and butyrylcholinesterase (pseudocholinesterase), enzymes that break down acetylcholine. This dual inhibition may provide more comprehensive cholinergic enhancement compared to other cholinesterase inhibitors that primarily target acetylcholinesterase.

Clinical Considerations

The transdermal patch provides more consistent drug levels and may reduce GI side effects compared to oral formulations. However, skin reactions are common with the patch. Dose titration must be gradual to minimize side effects, and the medication should be taken with food when using oral formulations. Regular monitoring for side effects and efficacy is important.

Prescribing Information

Dosing & Administration

Alzheimer’s Disease – Oral:

  • Initial: 1.5 mg twice daily with food
  • Titration: Increase by 1.5 mg twice daily every 2 weeks as tolerated
  • Target: 3-6 mg twice daily
  • Maximum: 6 mg twice daily

Parkinson’s Disease Dementia – Oral:

  • Initial: 1.5 mg twice daily with food
  • Titration: Same as Alzheimer’s disease
  • Target: 3-6 mg twice daily

Transdermal Patch:

  • Initial: 4.6 mg/24 hours patch
  • Titration: May increase to 9.5 mg/24 hours after minimum 4 weeks
  • Maximum: 13.3 mg/24 hours (for patients previously on highest oral doses)

Administration:

  • Oral: Take with morning and evening meals
  • Patch: Apply to clean, dry, hairless skin on back, chest, or upper arm
  • Patch rotation: Use different site each day, remove old patch before applying new

Indications

  • Treatment of mild to moderate dementia of the Alzheimer’s type
  • Treatment of mild to moderate dementia associated with Parkinson’s disease

Contraindications

  • Known hypersensitivity to rivastigmine, carbamate derivatives, or any component
  • History of application site reactions with rivastigmine patch suggestive of allergic contact dermatitis

Warnings & Precautions

  • Gastrointestinal effects: Nausea, vomiting, diarrhea, anorexia, weight loss
  • Skin reactions: Application site reactions with patch, potential for allergic contact dermatitis
  • Bradycardia: May cause heart rate slowing
  • Respiratory effects: Use caution in patients with asthma or COPD
  • Genitourinary effects: May worsen bladder outflow obstruction
  • Seizures: May increase seizure risk
  • Anesthesia: May enhance neuromuscular blocking effects

Drug Interactions

  • Anticholinergics: May reduce rivastigmine effectiveness
  • Cholinergic agonists: May enhance cholinergic effects
  • Beta-blockers: Additive bradycardic effects
  • NSAIDs: Increased risk of GI bleeding

Adverse Reactions

Common (≥5%) – Oral:

  • Nausea, vomiting, diarrhea, anorexia, weight loss
  • Dizziness, headache, somnolence

Common (≥5%) – Patch:

  • Nausea, vomiting, application site erythema
  • Diarrhea, anorexia, weight loss

Serious:

  • Severe skin reactions, significant weight loss, dehydration

Special Populations

  • Hepatic Impairment: Use caution, may require dose reduction
  • Renal Impairment: Use caution, may require dose reduction
  • Low body weight: Monitor closely for adverse effects
  • Pregnancy: Category B – use only if clearly needed
  • Patch application: Avoid heat exposure, rotate application sites
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.